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Abstract
Background: The goal of this study was to understand gene expression signatures of hepatocellular carcinoma
(HCC) recurrence in subjects with hepatitis C virus (HCV) infection. Recurrence-free survival (RFS) following curative
resection of HCC in subjects with HCV is highly variable. Traditional clinico-pathological endpoints are recognized
as weak predictors of RFS. It has been suggested that gene expression profiling of HCC and nontumoral liver tissue
may improve prediction of RFS, aid in understanding of the underlying liver disease, and guide individualized
patient management. Frozen samples of the tumors and nontumoral liver were obtained from 47 subjects with
HCV-associated HCC. Additional nontumoral liver samples were obtained from HCV-free subjects with metastatic
liver tumors. Gene expression profiling data was used to determine the molecular signature of HCV-associated
HCC and to develop a predictor of RFS.
Results: The molecular profile of the HCV-associated HCC confirmed central roles for MYC and TGFb1 in liver
tumor development. Gene expression in tumors was found to have poor predictive power with regards to RFS, but
analysis of nontumoral tissues yielded a strong predictor for RFS in late-recurring (>1 year) subjects. Importantly,
nontumoral tissue-derived gene expression predictor of RFS was highly significant in both univariable and
multivariable Cox proportional hazard model analyses.
Conclusions: Microarray analysis of the nontumoral tissues from subjects with HCV-associated HCC delivers novel
molecular signatures of RFS, especially among the late-recurrence subjects. The gene expression predictor may
hold important insights into the pathobiology of HCC recurrence and de novo tumor formation in cirrhotic
patients.
Background
Hepatocellular carcinoma (HCC) is the fifth most com-
mon cancer worldwide by annual incidence and the
third leading cause of cancer death [1]. Wide geographic
variation in age-adjusted incidence and death rates is
well recognized [2]. Most alarming is the fact that age-
adjusted incidence and death rates for cancer of the
liver and intrahepatic bile duct show a statistically sig-
nificant increasing trend in the past three decades in the
USA and many other countries, even though other
m a j o rc a n c e r sa r eo nad e c l i n e[ 3 ] .T h i sr i s ei sb e i n g
attributed, at least in part, to an increase in incidence of
hepatitis C virus (HCV) infections and non-alcoholic
steatohepatitis, pathological states that are also growing
in the US population [4,5]. The resistance of HCC to
existing treatments and the lack of biomarkers for early
detection make it one of the deadliest cancers. Surgical
resection, liver transplantation, and ablation by radiofre-
quency or ethanol injection are now conventional thera-
pies at early disease stages. Even with these options,
survival at 5 years is poor and ranges between 50% and
70% [6].
One of the key reasons for poor long-term survival in
HCC is high incidence of recurrence, a complication
that cannot be prevented effectively by new and existing
therapies [7,8]. Many clinico-pathological features, such
as tumor size, number of tumors in liver, capsule state,
cell differentiation, venous invasion, and the extent of
intrahepatic spreading are commonly used in clinical
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and health prognosis in patients [9,10]. However, the
prospective utility of these attributes for predicting
recurrence-free survival (RFS) may be more limited as
HCC is being diagnosed at earlier stages.
Several research groups have performed gene expres-
sion profiling of both tumor and nontumoral specimens
and identified gene signatures of recurrence-free [11], or
overall survival [12] in HCC patients who undergo
tumor resection. These studies carry an exciting poten-
tial to open the field to more selective chemoprevention
as a follow-up to surgical interventions since patients
with greatest risk of death or recurrence can be poten-
tially identified [12] and/or individualized therapies may
be devised based on the molecular profiles of poor-prog-
nosis markers of HCC [13,14]. At the same time, the
issues of validation of the molecular signatures, the uti-
lity of target-gene list strategy for predicting early- ver-
sus late-recurrence, and the value of these studies for
understanding pathobiology of the underlying liver dis-
ease in patients with HCC are still open for considera-
tion [15].
Thus, our study focused on a well-defined cohort of
HCC patients who were HCV positive (but free of hepa-
titis B virus) and underwent tumor resection to conduct
a comparative microarray-based gene expression profil-
ing of tumor and nontumoral specimens. We report the
molecular network signatures of HCV-associated HCC,
as well as the outcome of the analysis of the predictive
value of gene expression in tumor- and nontumoral tis-
sue-derived samples. This study was not only successful
i nd e v e l o p i n gah i g h l yp r e d i c t i v eR F Ss i g n a t u r ef o rl a t e
recurrence from nontumoral samples, but also shows
that this signature can be used for biological interpreta-
tion of the liver disease leading to recurrence.
Results and Discussion
Clinico-pathological markers of RFS in HCV-associated
HCC
This study evaluated specimens (frozen tumor and/or
nontumoral tissue) collected during liver tumor resec-
tion in (i) subjects with solitary tumors in liver that
were a result of metastasis from other organs, and (ii)
subjects manifesting HCC in combination with chronic
HCV infection and absence of known tumors at other
sites. Platelet count, alanine aminotransferase and fibro-
sis score were significantly different between the groups
(Table 1). The HCC cohort was subdivided into nontu-
moral and tumor groups for the purposes of molecular
analysis (see below). No differences between these two
groups, or between each group and the entire cohort,
exist based on the available clinical data. The univariable
analysis of the prognostic power for various clinico-
pathological measurements available in this study
showed that tumor stage, diameter and, to a lesser
degree, multiplicity were statistically significant in pre-
dicting the length of RFS in subjects with HCV-asso-
ciated HCC (Table 2). Other characteristics were not
significant, including the type of the surgical procedure
performed (e.g., lobular or segmental/partial hepatec-
tomy). These results are consistent with the reports in
the literature [16].
Molecular profiling of HCV-associated HCC
The importance of defining liver tumor biology that may
aid in the development of new screening and treatment
stratification programs to refine diagnosis and improve
patient outcome is well recognized [15]. Thus, our first
step was to evaluate gene expression data (25,073 tran-
scripts) collected on individual tumor and nontumoral
samples. Principal components analysis (Genomics
Suite; Partek Inc., St. Louis, MO) was used to examine
global variation in transcript abundance (Figure 1). The
unsupervised analysis displayed separation of the sam-
ples between HCC tumor samples and nontumoral sam-
ples from subjects with HCC and metastatic liver
tumors indicating that gene signatures indicative of
HCC tumor biology may be explored.
To evaluate the biological features of HCV-associated
HCC we compared gene expression profiles of tumors
and control (nontumoral tissue from metastatic liver
tumor) samples. The analysis revealed 155 up- and
1,248 down-regulated genes whose expression levels
were significantly different (FDR = 0). Next, functional
pathway analysis was performed using significant genes
(Additional file 1, Tables S2-3). Several pathways were
identified as significantly up- or down-regulated in
HCV-associated HCC. Interestingly, the top-ranked net-
work composed of up-regulated genes includes TGFb1
and MYC as hubs (Additional file 2, Figure S1). Indeed,
it has been suggested that chronic inflammation asso-
ciated with HCV infection in liver facilitates TGFb sig-
naling cascade involving c-Jun N-terminal kinase and
plasminogen activator inhibitor 1 which facilitates fibro-
genesis, promotes liver cirrhosis and increases the risk
of development of HCC [17]. In addition, gene expres-
sion-based comparison between dysplastic nodules and
early hepatocellular carcinomas identified the MYC
oncogene as a plausible driver gene for malignant trans-
formation of dysplastic nodules [18]. Thus, our data
provides independent confirmation of and strengthens
the evidence [19] for the key roles of TGFb1a n dM Y C
in the progression of HCC in patients with HCV.
Tumor-derived gene expression profiles and recurrence-
free survival in HCV-associated HCC
Recurrence of HCC is thought to arise due to intra-
hepatic metastasis, or the development of a second
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mitant disease [20]. The molecular signatures of the
tumor and its surrounding tissue, obtained through
gene expression, proteomics or other means of profiling,
are expected to reflect the causes of recurrence. Thus,
an important challenge is to develop better understand-
ing of the biological characteristics of the tumor and the
surrounding tissue and to use this information to pre-
dict the outcomes.
Indeed, gene expression profiling has been instrumen-
tal in tackling these challenges and it has been shown
that microarray analysis of the tumor samples can be
used for prediction of clinical outcomes in subjects with
HCC [21-23]. At the same time, others have reported
no success with tumor-based transcription profiling
[12]. Despite the fact that many clinical variables from
tumors such as number of tumors, tumor stage, and
tumor size were significantly associated with recurrence
(Table 2), univariable feature selection with Cox scores
did not identify robust markers of tumor recurrence in
the context of leave-one-out cross-validation either in
the entire cohort or in the sub-cohort of the early
Table 1 Clinical characteristics of patients.
Variables HCC Cohort
(N = 47)
Nontumoral HCC cohort
(N = 44)
Tumor HCC cohort
(N = 43)
Control liver cohort (metastatic liver tumors,
N=8 )
Age 66.5 ± 7.8 66.4 ± 7.9 66.5 ± 7.9 60.0 ± 13.5
Gender
Male 35 (74.4%) 32 (72.7%) 32 (74.4%) 4 (50.0%)
Female 12 (25.5%) 12 (27.3%) 11 (25.6%) 4 (50.0%)
Viral infection status
HBV infection - - - -
HCV infection + + + -
Liver resection procedure
Lobular/extended lobular 5 5 5 N/A
Segmental/partial 42 39 38
Platelet count (10
4/μl) 12.9 ± 4.3 13.0 ± 4.2 12.8 ± 4.2 19.3+3.6*
Alanine aminotransferase (IU/l) 51.0 ± 31.7 51.0 ± 32.0 51.7 ± 33.1 19.7+7.7*
Total bilirubin (mg/dl) 0.80 ± 0.34 0.76 ± 0.30 0.80 ± 0.35 0.85+0.37
Prothrombin time (%) 78.3 ± 13.1 78.3 ± 12.9 78.1 ± 13.3 91.1+14.5
Indocyanine green (%) 18.4 ± 8.3 18.5 ± 8.3 18.3 ± 8.4 11.0+5.3
a-Fetoprotein (ng/ml) 319 ± 924 339 ± 952 345 ± 962 N/A
Tumor diameter (cm) 2.90 ± 1.30 2.97 ± 1.35 2.95 ± 1.37 N/A
Number of tumors 1.30 ± 0.50 1.32 ± 0.52 1.30 ± 0.51 N/A
Portal vein invasion
Present 5 (10.6%) 5 (11.4%) 5 (11.6%) N/A
Absent 42 (89.4%) 39 (88.6%) 38 (88.4%) N/A
Tumor stage
I 9 (19.1%) 9 (20.5%) 8 (18.6%) N/A
II 25 (53.2%) 23 (52.3%) 24 (55.8%) N/A
III 12 (25.5%) 11 (25.0%) 10 (23.3%) N/A
IV 1 (2.1%) 1 (2.3%) 1 (2.3%) N/A
Tumor differentiation
Well differentiated 8 (17.0%) 8 (18.2%) 6 (14.0%) N/A
Moderately differentiated 31 (66.0%) 28 (63.6%) 29 (67.4%) N/A
Poorly differentiated 8 (17.0%) 8 (18.2%) 8 (18.6%) N/A
Fibrosis score
F0 0 (0%) 0 (0%) 0 (0%) 8 (100%)*
F1 3 (6.4%) 3 (6.8%) 3 (7.0%) 0 (0%)
F2 6 (12.8%) 5 (11.4%) 6 (14.0%) 0 (0%)
F3 14 (29.8%) 14 (31.8%) 12 (27.9%) 0 (0%)
F4 24 (51.1%) 22 (50.0%) 22 (51.2%) 0 (0%)
Data shown are mean ± standard deviation. N/A, data is not available. Asterisk(*) denotes statistical difference from other groups (ANOVA, p < 0.05).
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reasons for our inability to create a predictor with
tumor samples alone may include, among other factors,
small sample size compounded by the considerable het-
erogeneity of gene expression between tumor samples
(Additional file 2, Figure S2). However, our result is
similar to the observations of Hoshida et al. [12] who
also were unable to establish a tumor-derived predictor
even with a much larger (hundreds of subjects) cohort.
A l t h o u g ht h e s er e s u l t sd on o tn e g a t et h ev a l u eo f
tumor-derived expression profiling in predicting the
outcomes of HCC, the data suggest that, at least in the
cohort of HCV-positive HCC, tumor profiling alone
may have limited value with regards to RFS.
Nonetheless, to further characterize the pathobiology
of HCC recurrence we applied the gene set analysis algo-
rithm to tumor-derived gene expression data in order to
determine whether biologically-relevant gene sets that
correlate with RFS exist. There were 1,497 gene sets
based on 25,073 transcripts and a Cox score was gener-
ated for each gene set. Based on the nearest template pre-
diction and leave-one-out cross-validation (i.e.,
independent prediction of each sample), several top-
ranked (based on Cox score) gene sets were found to be
predictive of tumor recurrence (Additional file 2, Figure
S3). The gene set analysis has great value for assessment
of the molecular profiles of the aggressively recurring
tumors and may improve our understanding of the
underlying biology that may be associated with the poor
outcomes. Indeed, the most predictive gene set-based
survival signature from HCC samples (Additional file 1,
Table S4) contains a number of known key cancer-pro-
moting pathways, such as mTOR [24], TGFb [17], DNA
damage response [25], hypoxia [26], histone deacetylase
[27], and MET [28]. This data suggests that key tumor-
related genes may not only be involved in tumorigenesis,
but may also be important for recurrence and thus can
be used for selection of the subjects with poor prognosis.
Table 2 Univariate analysis of clinico-pathological prognostic markers associated with recurrence-free survival in
patients with HCC.
Nontumoral HCC Cohort (N = 44) Tumor HCC Cohort (N = 43)
Risk ratio 95% CI P-value Risk ratio 95% CI P-value
Tumor stage 2.48 1.39-4.51 0.002 2.54 1.41-4.70 0.002
Tumor diameter 1.59 1.17-2.09 0.005 1.65 1.19-2.24 0.004
Number of tumors 2.41 1.17-4.68 0.02 2.10 0.99-4.19 0.05
Platelet count 0.95 0.87-1.03 0.22 0.97 0.89-1.06 0.53
Sex [male] 1.44 0.67-3.43 0.36 1.62 0.74-4.08 0.24
Indocyanine green 1.02 0.97-1.06 0.40 1.01 0.97-1.05 0.56
Prothrombin time 0.99 0.97-1.02 0.45 0.99 0.97-1.02 0.40
Portal vein invasion [present] 1.41 0.33-4.06 0.59 1.42 0.34-4.08 0.59
Liver resection procedure [lobular] 1.14 0.62-1.82 0.65 1.13 0.61-1.81 0.66
Total Bilirubin 1.26 0.42-3.24 0.66 1.35 0.50-3.19 0.54
Fibrosis score 0.96 0.65-1.49 0.86 0.92 0.63-1.38 0.67
Tumor differentiation [moderate-poor] 1.08 0.47-2.93 0.86 0.84 0.35-2.49 0.73
Age 1.00 0.96-1.05 0.90 1.02 0.97-1.07 0.53
Alanine aminotransferase 1.00 0.99-1.01 0.96 1.00 0.99-1.01 0.94
a-Fetoprotein 1.00 1.00-1.00 0.99 1.00 1.00-1.00 0.90
Patients with HCV-associated HCC were divided into two cohorts based on the availability of mRNA samples. Univariate Cox proportional hazard model analysis
was used to assess relative risk for each clinical variable. Relative risk >1 identifies shortened recurrence-free survival. Significant variables are highlighted in bold.
Figure 1 Principal components analysis of the liver tumoral
and non-tumoral transcriptome. Global gene expression (25,073
genes) data of the samples from HCC (black circle), surgical margin-
derived nontumoral samples (white circle), and control samples
(nontumoral samples from patients with metastatic liver tumors;
black triangle) was visualized using principal components analysis.
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recurrence-free survival in HCV-associated HCC
Tumor-derived gene expression profiles did not produce
a robust classifier of RFS in this cohort. This result led
us to consider whether the surrounding liver tissue, not
the tumor itself, may yield a molecular predictor asso-
ciated with HCC recurrence. Indeed, several previous
studies have shown that nontumoral tissue profiling in
HCC holds great promise with regards to predicting
clinical outcomes [11,12,29]. Forty-four nontumoral
samples (94% of the entire subject cohort) yielded high-
quality gene expression profiles. When both early- and
late-recurrence samples were analyzed together, signa-
tures composed of up to 18 top-ranked genes that cor-
relate with disease-free survival were derived (Figure 2).
The strongest signature (Figure 2B, p = 0.02 based on
prediction during cross-validation) with the fewest num-
ber of genes is comprised of 14 genes (Figure 2C).
It has been suggested that distinct gene expression sig-
natures may exist for prediction of early and late recur-
rence [15]. This is exemplified by the fact that little
overlap exists between nontumoral tissue-derived signa-
tures for predicting metastasis-related early recurrence
[29], as opposed to those predictive of risk for the late
recurrence [12]. Since late recurrence in HCV-infected
subjects is likely to be through de novo formation of
tumors in the diseased liver, we selected a sub-cohort of
28 patents with late (>1 year) recurrence and repeated
the cross-validation procedure at both gene and gene
set level. Even though a more traditional cut-off for
“late” recurrence is 2 years, recent meta-analysis of HCC
molecular subclasses suggests that 1 year time point
may represent a more biologically-defined cut-off [19].
When individual transcript-level data was used, very
strong predictive signatures could be derived for up to
91 genes (Additional file 2, Figure S4; Additional file 1,
Table S5). All of the predictors composed of less than
38 genes were highly significant with 11 top-ranked
genes producing the strongest signature (Figures 3A-C,
p < 0.0001 based on cross-validation, 0% error rate).
Importantly, the genes identified as the strongest predic-
tors of RFS that were over expressed in subjects with
fastest recurrence have been previously implicated in
tumor pathogenesis. For example, megakaryoblastic leu-
kemia factor (MKL)1 has been shown to be required for
TGFb1 stimulation of alpha-smooth muscle actin
expression [30], a process which promotes liver fibrosis
and cirrhosis. TNKS1BP1 is a tankyrase 1-binding pro-
tein and it is known that tankyrase 1 upregulation leads
to enhanced access of telomerase to telomeres and pro-
motes clonal expansion of cancer cells [31]. Scaffold
attachment factor B (SAFB) is playing a role in tran-
scriptional repression and RNA splicing, and has been
shown to be important in numerous cancer-related
cellular processes including cell growth, stress response,
and apoptosis [32]. Protein phosphatase 2, regulatory
subunit B, gamma isoform (PPP2R5C) was shown to
function as a tumor suppressor gene. Upon DNA
damage, a complex including PPP2R5C and p53 is
formed which leads to dephosphorylation of p53, induc-
tion of the p53 transcriptional target p21, and the inhi-
bition of cell proliferation [33].
Figure 2 Recurrence-free survival analysis in the full cohort of
HCC patients (N = 44) using gene expression in nontumoral
samples. Expression of 25,073 genes was used as a variable in Cox
proportional hazard model. The power of recurrence-free survival
prediction for the top-ranked (based on Cox score) genes was
assessed using the Nearest Template Prediction (NTP) algorithm and
cross-validated with a leave-one-out procedure. (A) Log-rank P-value
and error rate of prediction for up to 150 top-ranked genes. (B)
Recurrence-free survival curves based of the prediction made using
14 top-ranked genes. (C) Heat map of the 14 gene-based predictors.
Red and blue indicate higher or lower than median gene
expression, respectively.
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gene expression signatures of recurrence-free survival in
HCV-associated HCC
The poor-prognosis late recurrence signature composed
of 11, 38 or 91 top-ranked genes (Figure 3A), along with
clinical variables available for the cohort of 28 subjects
with recurrence >1 year, was analyzed by univariable
Cox-proportional hazard model. Each of the gene
expression-based poor-prognosis signatures, tumor
diameter and the number of tumors were significantly
associated with risk of recurrence in a univariable analy-
sis (Table 3). Next, we examined the signatures in con-
text of the clinical variables that were significant in our
study and are also generally accepted as indicative of
poor prognosis for recurrence of HCC. Importantly, a
multivariable analysis (based on independent prediction
of each sample using the cross-validation procedure as
detailed above) of each set of top-ranked gene lists
Figure 3 Recurrence-free survival analysis in HCC patients with late (>1 year) recurrence using gene expression in nontumoral
samples. (A and D) Logrank P-value and error rate of prediction for up to 150 top-ranked genes or gene sets. (B and E) Recurrence-free survival
curves based of the prediction made using top-ranked genes (11) or gene sets (120), respectively (see Additional file 1, Tables S5-6 for the lists).
(C and F) Heat map of the gene-, or gene set-based predictors. Red and blue indicate higher or lower than median gene expression,
respectively.
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of tumors and tumor diameter) showed that the late
recurrence signatures composed of 11 and 38 genes, but
not 91 genes, remained significant.
Molecular predictors of tumor recurrence: clinical
diagnostic tools or keys to tumor biology?
Identification of gene expression signatures as predictors
o ft h ed i s e a s eo u t c o m eh a sb e e nav e r ya c t i v ea r e ao f
clinical cancer research [15,34]. The gene expression sig-
natures outperform conventional clinicopathologic
criteria in high-risk patients and help differentiate treat-
ment options by identifying low-risk individuals [35].
Interestingly, while the signatures usually address the
same clinical question, there is only little or no overlap
in gene lists derived from different cohorts [15,36].
Most of the individual studies, including our work, are
relatively small in size which may limit the potential for
direct translation of the molecular signatures to the
individual cancer patient management. To address this
challenge, large comprehensive meta-analyses integrating
both the gene expression and clinicopathologic data
from multiple studies have been conducted for breast
[35,36], lung [34] and other cancers.
Indeed, a comparison of the applicability of the poor-
prognosis signatures from this study to the independent
HCC cohort is the ultimate test for the ‘biological’ vali-
dation of the findings. There are two published microar-
ray datasets that profiled nontumoral tissues from HCC
subjects as potentially suitable for validation [11,12]
which may be used for cross-study validation. Unfortu-
nately, the microarray used by Okamoto et al. [11] lacks
comprehensive publicly accessible annotation (Agilent
Technologies, personal communications) rendering any
meaningful comparison between studies futile. The sec-
ond study by Hoshida et al. [12] was conducted on for-
malin-fixed samples and used a specialized microarray
containing ~6,000 probes. Not only there is only limited
(~20%) overlap in transcripts between the Illumina array
(GPL5474, http://www.ncbi.nlm.nih.gov/geo/) and the
whole human genome (~44,000 probes) Agilent array
used in our work, but also the clinico-pathological vari-
ables of the patient cohort used by the authors have not
been released to the public (personal communication).
Thus, while the cross-study comparisons shall remain as
the goal for validation of the findings reported on inde-
pendent cohorts and array platforms, greater degree of
collaboration may be needed in the field of liver tumor
biology.
While the molecular signatures generated in this study
may not be clinic-ready without additional meta-analysis
once the data becomes publicly available, we posit that
late recurrence predictive genes may provide new
insights into the oncogenic pathways for HCC develop-
ment in cirrhotic patients. By examining the biological
roles of the predictive genes it may be possible to better
understand the process of field cancerization in HCC
[37,38] and a transition from cirrhosis to HCC. First,
functional pathway analysis was performed using 91
top-ranked genes (Additional file 2, Figure S4; Addi-
tional file 1, Table S5) which comprise a comprehensive
poor-prognosis signature in nontumoral tissues from
subjects with late (>1 year) recurrence (Figure 4 and
Additional file 1, Table S7). Interestingly, hepatic
nuclear factor (HNF)4a- and interferon (IFN)g-centered
Table 3 Association of gene expression poor-prognosis
signature and clinical variables with late (>1 year)
recurrence from univariate or multivariate analyses.
Variable Risk
ratio
95% CI P-value
Univariate Cox proportional hazard
model
RFS signature (11 genes) 3.13 1.75-6.58 <0.0001
RFS signature (38 genes) 2.05 1.24-3.54 0.005
RFS signature (91 genes) 1.64 1.02-2.71 0.04
Tumor diameter [cm] 2.19 1.20-3.95 0.01
Number of tumors 4.28 1.24-
13.39
0.02
Platelet count [10
4/μL] 0.91 0.80-1.02 0.11
Portal vein invasion [present] 0.00 0.00-1.93 0.15
Total bilirubin [mg/dL] 1.54 0.37-4.97 0.52
Age 1.02 0.96-1.10 0.53
Alanine aminotransferase [IU/L] 0.99 0.97-1.01 0.55
Indocyanine green [%] 1.02 0.95-1.08 0.56
Prothrombin time [%] 0.99 0.96-1.03 0.64
Liver resection procedure [lobular] 1.16 0.46-2.21 0.71
Fibrosis score 0.93 0.52-1.72 0.80
a-Fetoprotein [ng/μL] 1.00 1.00-1.00 0.85
Tumor differentiation [moderate-poor] 0.91 0.32-3.27 0.87
Sex [Male] 0.93 0.35-2.71 0.89
Multivariate Cox proportional hazard
model
RFS signature (11 genes) 3.38 1.75-7.77 0.0001
Number of tumors 8.55 1.87-
46.69
0.006
Tumor diameter [cm] 1.68 0.92-3.19 0.09
RFS signature (38 genes) 1.84 1.08-3.23 0.02
Number of tumors 4.59 1.23-
16.11
0.02
Tumor diameter [cm] 2.12 1.15-4.03 0.02
RFS signature (91 genes) 1.53 0.93-2.60 0.09
Number of tumors 3.58 0.98-12.3 0.05
Tumor diameter [cm] 2.46 1.30-4.70 0.006
Cox proportional hazard model analysis was used to assess relative risk for
each clinical variable or RFS gene expression signature. Relative risk >1
identifies shortened recurrence-free survival. Significant variables are
highlighted in bold font.
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nected networks (Figure 4A). Expression of HNF4a is
an important determinant of HCC progression and the
development of aggressive tumor phenotypes in mice
[39], while the T-helper 1 inflammatory cells character-
ized by IFNg secretion predominate in the liver during
chronic HCV infection and are particularly important in
disease progression [40]. The TP53-centered interac-
tome is the top third significant network (Figure 4B)
and the role of TP53 tumor suppressor pathway is
widely recognized as significant contributors to liver car-
cinogenesis [41].
Second, gene set analysis was used to evaluate the data
from the sub-cohort of late (>1 year) recurrence subjects
(Figures 3D-F). A number of top-ranked gene sets can
serve as predictors (Additional file 1, Table S6) with the
profile composed of 120 gene sets being most significant
(p = 0.002) with the smallest error rate. Importantly, the
gene set-based signature is overabundant in upregulated
inflammation- (e.g., nuclear factor-B, tumor necrosis
factor), oxidative stress-, and carcinogenesis- (MYC,
MAP kinase) related pathways, and down-regulated cell
cycle control-related and protesome pathways. Interest-
ingly, there appears to be great overlap in gene sets
associated with poor prognosis outcome between nontu-
moral tissue and tumors (see Additional file 2, Figure
S3, Additional file 1, Table S4) which further supports
the theory of field cancerization and progression from
cirrhosis to HCC.
Conclusions
Our study demonstrates that microarray analysis of the
nontumoral tissues from subjects with HCV-associated
HCC delivers novel molecular signatures of RFS, espe-
cially among the late-recurrence subjects. Since late
recurrence is likely a de novo tumor occurrence in
HCV-associated cirrhosis, the biopsy-based gene expres-
sion analysis in cirrhotic patients may be a useful
method to stratify the risk of tumor occurrence and
determine a need for aggressive patient screening. While
challenges remain in validating the signatures and trans-
lating the findings to clinical practice, we posit that
gene expression-based signatures provide important
insights into pathobiology of HCC recurrence.
Methods
Subjects, specimen collection and study design
Forty-seven subjects with HCV-associated HCC who
underwent complete removal of the tumor at the Uni-
versity of Yamanashi Hospital (Yamanashi Prefecture,
Japan) between 2000 and 2007 were enrolled in this
study. All of the subjects tested positive for HCV and
negative for hepatitis B virus. The presence and identifi-
cation of the hepatitis virus was determined by one or
more of the following techniques: (i) presence of anti-
HCV and anti-HBV reactive serum proteins, (ii) reverse
transcription-PCR for serum HCV-RNA, or (iii)
branched DNA-HCV probe assay. Following the tumor
resection procedure and recovery after surgery, each
subject visited the ambulatory care clinic for additional
tests monthly. Serum a-fetoprotein levels were mea-
sured every month. In addition, ultrasonography or
computed tomography of the liver was performed every
3 and 6 months, respectively. Eight HCV- and HBV-free
subjects who were diagnosed with metastatic liver
tumors that required surgical resection were enrolled as
Figure 4 Molecular networks representing the RFS gene
expression signature (91 genes) in HCC patients with late (>1
year) recurrence. See Additional file 1, Table S7 for a complete list
of significant networks. (A) HNF4a- and IFNg-centered interactomes
are top two most significant and interconnected (orange arrows)
networks. (B) TP53-centered interactome is the top third significant
network. Red and blue colors indicate positive or negative
correlation, respectively, of gene expressions to recurrence-free
survival based on Cox score. Ellipse, square, triangle, trapezoid,
lozenge and circle represent transcription regulator, cytokine, kinase,
transporter, enzyme and other molecules, respectively. Red and
white represent molecules up-regulated in tumor samples
compared to control and molecules incorporated into the network,
respectively. Arrows connecting molecules indicate one molecule
acts on another and lines indicate one binds to another. Dashed
arrows or lines indicate indirect interactions of two molecules.
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obtained. All samples were frozen in liquid nitrogen
immediately following surgery and kept as -80°C until
processed. Informed consent was received from each
subject in the study and the study protocol conforms to
the ethical guidelines of the 1975 Declaration of Hel-
sinki as reflected in an a priori approval by the Institu-
tional Board on Ethics for Human Science at the
University of Yamanashi. All available clinical data for
the subjects enrolled in this study are summarized in
T a b l e1 .R F Sd a t aa r ep r o v i d e di nA d d i t i o n a lf i l e1 ,
Table S1.
Statistical analysis
JMP software (ver. 6.0, SAS institute, Cary, NC) was
used for statistical analysis of the clinical and molecular
(see below) variables. For univariable analysis, two-sam-
ple t-test, linear regression, or Logrank test statistical
procedures were used to assess what endpoints could be
used for predicting prognosis of HCC subjects after sur-
gery. For multivariable analysis, the Cox proportional
hazard model was used to calculate hazard ratio and p-
value of each parameter. A p value of less than 0.05 was
considered significant.
Microarray analysis
Total RNA was isolated from tumor and nontumoral
liver samples (~30 mg) with an RNeasy plus mini kit
(Qiagen, Valencia, CA) as detailed by the manufacturer.
High quality RNAs was obtained from 43 tumor and 44
nontumoral samples (40 tumor and nontumoral RNA
samples were from the same subjects). For microarray
analysis, a balanced design was used. Each batch of
arrays (Agilent Technologies, Wilmington, DE; whole
human genome microarray, cat.#G4112F) was balanced
with regards to the tumor stage and RFS and contained
both inter-batch and intra-batch replicates.
RNA samples were hybridized to arrays individually;
none were pooled. RNA amplifications and labeling
were performed using Low RNA Input Linear Amplifi-
cation kits (Agilent Technologies). For hybridization, 1.2
μg of total RNA from each sample, or human reference
RNA (Stratagene, La Jolla, CA; Cat#740000) was ampli-
fied and labeled with fluorescent dye (Cy5 and Cy3,
respectively). RNA labeling, microarray hybridization,
washing and scanning were performed according to the
manufacturer’s instructions. Feature extraction, normali-
zation of the raw data and data filtering were performed
using the Agilent Feature Extraction software (v8.5, Agi-
lent Technologies). Raw microarray data was archived in
Gene Expression Omnibus (GSE17856) and is available
to the public. The log2 ratio of Cy5/Cy3 intensity was
normalized using LOWESS smoothing to eliminate
intensity bias of features. Transcripts with fewer than
70% available data across samples were excluded from
the analysis, reducing the probe list to 25,073 tran-
scripts. Available data are defined as those probes that
are neither saturated nor below the limit of quantifica-
tion. Inter-batch normalization was carried out using
Distance Weighted Discrimination procedure [42].
Biological pathway analysis on tumor samples
Differentially expressed genes between control and
tumor sample groups were identified by using Signifi-
cant Analysis of Microarray analysis [43]. Individual
genes with false discovery rate (FDR) = 0 in the univari-
able test under 1,000 random permutations were consid-
ered significant. Selected genes were analyzed using
Ingenuity Pathways Analysis (v. 7.1; Ingenuity Systems,
Redwood City, CA) to determine canonical pathways
that are enriched among the significant transcripts.
SAFEGUI [44] was used to compare gene expression
level between HCC tumor samples and control nontu-
moral liver samples from subjects with metastatic liver
tumors based on Gene Ontology (GO) biological pro-
cess categories, or Kyoto Encyclopedia of Genes and
Genomes (KEGG) pathways. P-values less than 0.01
were considered to be significant.
Gene expression-based recurrence-free survival (RFS)
predictor
Tumor and adjacent nontumoral liver tissues were con-
sidered separately to define an RFS-predictive signature
on each type of tissue. In each dataset, genes whose
expression was associated with time to recurrence were
selected by means of the high absolute Cox score and
prediction analysis was performed by evaluating the
expression status of the signature using the nearest tem-
plate prediction method as described elsewhere[12] and
implemented in GenePattern software (ver.3.1.1, http://
www.broad.mit.edu/cancer/software/genepattern/). The
signatures were validated using a leave-one-out cross-
validation prediction procedure. In brief, each sample
was left out one-by-one and a disease-free survival-cor-
related signature was deduced using remaining samples
(selecting marker genes based on top-ranked highest
absolute Cox score). A predicted class label was assigned
to the left-out sample based on the closest “template”
using the nearest template prediction algorithm. A max-
imum of 200 top-ranked genes were used to make
predictions in each analysis. The outcome of cross-vali-
dation based prediction was assessed by Logrank test
and the “error rate,” defined here as the ratio of the
number of subjects predicted incorrectly to that in the
model. In parallel, the “gene set” analysis (GSA) was
also used to determine the significance of pre-defined
sets of genes with respect to an outcome variable, such
as a RFS time. GSA package for R http://www-stat.
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GSA was used to generate RFS predictors in the same
manner as detailed above for gene-level data and vali-
dated using a leave-one-out cross-validation procedure.
List of Abbreviations
HCC: Hepatocellular Carcinoma; HCV: Hepatitis C
Virus; FDR: False Discovery Rate; GO: Gene Ontology;
KEGG: Kyoto Encyclopedia of Genes and Genomes;
RFS: Recurrence-Free Survival; SAFE: Significance Ana-
lysis of Function and Expression.
Additional file 1: table S1. Clinical outcomes for each individual patient
included in this study. table S2. Molecular networks (Ingenuity® pathways
analysis) differentially modulated between control (nontumoral samples
from patients with metastatic liver tumors) tissue and HCC tumors. table
S3. GO categories and KEGG pathways that differ significantly between
control and HCC tumor samples were identified using SAFE analysis (see
Methods). table S4. Sixty seven top-ranked gene sets used for recurrence
prediction analysis in tumor samples (see Figure 3C for the heat map).
table S5. Ninety one top-ranked genes used for recurrence prediction
analysis in nontumoral samples from late (>1 year) recurrence subjects
(see Figure 3C for the heat map). table S6. One hundred twenty top-
ranked gene sets used for recurrence prediction analysis in nontumoral
samples from late (>1 year) recurrence subjects (see Figure 3F for the
heat map). table S7. Molecular networks representing the recurrence-free
survival gene expression signature (91 genes) in HCC patients with late
(>1 year) recurrence.
Additional file 2: Figure S1. TGFb1- and MYC-centered interactomes are
most significantly up-regulated molecular networks in HCC tumors (see
Additional file 1, Table S2-3 for a full list of the significant pathways).
Ellipse, square, triangle, trapezoid, lozenge and circle represent
transcription regulator, cytokine, kinase, transporter, enzyme and other
molecules, respectively. Red and white represent molecules up-regulated
in tumor samples compared to control and molecules incorporated into
the network, respectively. Arrows connecting molecules indicate one
molecule acts on another and lines indicate one binds to another.
Dashed arrows or lines indicate indirect interactions of two molecules.
Figure S2. Analysis of the dissimilarity (Spearman’s correlation) between
gene expression profiles of the nontumoral (top) or tumoral (bottom)
samples used in this study. Expression of 25,073 genes was used as a
variable to create the heat map of each dissimilarity matrix. The color bar
represents the degree of dissimilarity with red exhibiting high degree of
dissimilarity and blue - high similarity. Figure S3. Recurrence-free survival
analysis in HCC patients using gene set analysis in tumor samples. (A)
Logrank P-value and error rate of prediction for up to 150 top-ranked
gene sets. (B) Recurrence-free survival curves (Kaplan-Meier method)
based of the prediction made using 67 top-ranked gene sets (Additional
file 1, Table S4). Red and blue represent the subjects predicted to have
poor or good recurrence-free survival, respectively. (C) Heatmap of the
67 gene set-based survival signature from tumor samples. Red and blue
indicate high or low gene set score, respectively. Subjects (x-axis) are
sorted by means of cosine distance to ‘poor’ template, and gene sets
(y-axis) are sorted by Cox score (Additional file 1, Table S4). Figure S4.
Recurrence-free survival analysis in HCC patients with late (>1 year)
recurrence using gene expression (91 genes) in nontumoral samples. (A)
91 genes selected based on log-rank P-value and error rate of prediction
were used to construct recurrence-free survival curves (B). (C) Heat map
of the gene-based survival signature with 91 genes.
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